These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26043228)

  • 21. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
    Astrup A; Carraro R; Finer N; Harper A; Kunesova M; Lean ME; Niskanen L; Rasmussen MF; Rissanen A; Rössner S; Savolainen MJ; Van Gaal L;
    Int J Obes (Lond); 2012 Jun; 36(6):843-54. PubMed ID: 21844879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.
    Hansen HH; Hansen G; Paulsen S; Vrang N; Mark M; Jelsing J; Klein T
    Eur J Pharmacol; 2014 Oct; 741():254-63. PubMed ID: 25160746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
    Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
    Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
    Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
    Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of gastrointestinal hormones in postprandial reduction of bone resorption.
    Henriksen DB; Alexandersen P; Bjarnason NH; Vilsbøll T; Hartmann B; Henriksen EE; Byrjalsen I; Krarup T; Holst JJ; Christiansen C
    J Bone Miner Res; 2003 Dec; 18(12):2180-9. PubMed ID: 14672353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
    Hegedüs L; Moses AC; Zdravkovic M; Le Thi T; Daniels GH
    J Clin Endocrinol Metab; 2011 Mar; 96(3):853-60. PubMed ID: 21209033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
    Andersen E; Juhl CR; Kjøller ET; Lundgren JR; Janus C; Dehestani Y; Saupstad M; Ingerslev LR; Duun OM; Jensen SBK; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS; Barrès R
    Hum Reprod; 2022 Jun; 37(7):1414-1422. PubMed ID: 35580859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.
    Ma X; Meng J; Jia M; Bi L; Zhou Y; Wang Y; Hu J; He G; Luo X
    J Bone Miner Res; 2013 Jul; 28(7):1641-52. PubMed ID: 23427056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
    Kahal H; Abouda G; Rigby AS; Coady AM; Kilpatrick ES; Atkin SL
    Clin Endocrinol (Oxf); 2014 Oct; 81(4):523-8. PubMed ID: 24256515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36.
    Iepsen EW; Lundgren J; Holst JJ; Madsbad S; Torekov SS
    Eur J Endocrinol; 2016 Jun; 174(6):775-84. PubMed ID: 26976129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.
    Jensen SBK; Lundgren JR; Janus C; Juhl CR; Olsen LM; Rosenkilde M; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS
    BMJ Open; 2019 Nov; 9(11):e031431. PubMed ID: 31678947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects.
    de Luis DA; Gonzalez Sagrado M; Conde R; Aller R; Izaola O
    Ann Nutr Metab; 2007; 51(2):134-8. PubMed ID: 17536190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
    Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
    Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
    Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
    Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
    Silver HJ; Olson D; Mayfield D; Wright P; Nian H; Mashayekhi M; Koethe JR; Niswender KD; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Aug; 25(8):2340-2350. PubMed ID: 37188932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.